Article Details
Retrieved on: 2020-12-28 17:35:13
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The Kinnate Biopharma Thesis: Kinnate Biopharma's lead asset KIN002787, which targets BRAF Class II and Class III mutations, addresses a high ...
Article found on: www.benzinga.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here